Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
Open Access
- 10 December 2022
- journal article
- editorial
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 10 (2) , 301-306
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Not your average joint: Towards precision medicine in psoriatic arthritisClinical Immunology, 2020
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateAnnals of the Rheumatic Diseases, 2020
- Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?The Journal of Rheumatology, 2019
- Residual Disease Activity and Associated Factors in Psoriatic ArthritisThe Journal of Rheumatology, 2019
- Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory DiseaseAdvances in Therapy, 2018
- Psoriatic arthritis: is it time to treat-to-target or target to treat?Clinical Rheumatology, 2017
- Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal CohortThe Journal of Rheumatology, 2017
- The role of IL-17 in the treatment of psoriatic arthritisExpert Review of Clinical Immunology, 2017
- Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic reviewSeminars in Arthritis and Rheumatism, 2015
- Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year studyRheumatology, 2010